

Site of Care Medications

Site of Care ensures that members are provided the opportunity to receive the highest quality, lowest cost access to care when receiving these medically appropriate medications. Requests for a site of care other than a non-hospital based facility are reviewed for medical necessity. Non-hospital based facilities may include a physician's office or ambulatory infusion center. This list requiring Site of Care review includes infused or injected medications that are administered by a healthcare provider. A review for prior authorization may also apply to certain medications listed. The policy does not apply to members under the age of 18.

Drug Name	J Code	Drug Category
Actemra	J3262	Anti-inflammatory Monoclonal Antibody
Advate	J7192	Antihemophilic Agent
Adynovate	J7207	Antihemophilic Agent
Aldurazyme	J1931	Lysosomal Storage Disorders
Alphanate	J7186	Antihemophilic Agent
AlphaNine	J7193	Antihemophilic Agent
Alprolix	J7201	Antihemophilic Agent
Aralast NP	J0256	Alpha-1 Proteinase Inhibitors
Avsola	Q5121	Immunosuppressive Agent
Bebulin	J7194	Antihemophilic Agent
Benefix	J7195	Antihemophilic Agent
Benlysta IV	J0490	Systemic Lupus Erythematosus Monoclonal Antibody Agent
Berinert	J0597	Hereditary Angioedema Agent (HAE)
Bivigam	J1556	Blood product derivative/ Immune Globulin
Carimune	J1566	Blood product derivative/ Immune Globulin
Cerezyme	J1786	Lysosomal Storage Disorders
Cinqair	J2786	Anti-Asthmatic Monoclonal Antibody
Cinryze	J0598	Hereditary Angioedema Agent (HAE)
Coagadex	J7175	Antihemophilic Agent
Crysvita	J0584	Hypophosphatemia Monoclonal Antibody Agent
Cuvitru	J1555	Blood product derivative/ Immune Globulin
Elaprase	J1743	Lysosomal Storage Disorders
Elelyso	J3060	Lysosomal Storage Disorders
Eloctate	J7205	Antihemophilic Agent
Entyvio	J3380	Monoclonal Antibody GI Agent
Evenity	Not established	Monoclonal Antibody Bone-Modifying Agent
Exondys 51	J1428	Duchenne muscular dystrophy
Fabrazyme	J0180	Fabry Disease
Fasenra	J0517	Anti-Asthmatic Monoclonal Antibody

Site of Care Medications

Site of Care ensures that members are provided the opportunity to receive the highest quality, lowest cost access to care when receiving these medically appropriate medications. Requests for a site of care other than a non-hospital based facility are reviewed for medical necessity. Non-hospital based facilities may include a physician's office or ambulatory infusion center. This list requiring Site of Care review includes infused or injected medications that are administered by a healthcare provider. A review for prior authorization may also apply to certain medications listed. The policy does not apply to members under the age of 18.

Feiba	J7198	Antihemophilic Agent
Firazyr	J1744	Hereditary Angioedema Agent (HAE)
Flebogamma	J1572	Blood product derivative/ Immune Globulin
Flolan	J1325	Prostacyclin Agent
Fulphila	Q5108	Hematopoietic Growth Factor Agents
Gammagard	J1569	Blood product derivative/ Immune Globulin
Gammaked	J1561	Blood product derivative/ Immune Globulin
Gammaplex	J1557	Blood product derivative/ Immune Globulin
Gamunex	J1561	Blood product derivative/ Immune Globulin
Genotropin	J2941	Growth Hormone
Glassia	J0257	Alpha-1 Proteinase Inhibitors
Granix	J1447	Hematopoietic Growth Factor Agents
H.P. Acthar Gel	J0800	Adrenocorticotropin Stimulating Hormone
Haegarda	J0599	Hereditary Angioedema Agent (HAE)
Helixate	J7192	Antihemophilic Agent
Hemlibra	J7170	Antihemophilic Agent
Hizentra	J1559	Blood product derivative/ Immune Globulin
Humate-P	J7187	Antihemophilic Agent
Humatrope	J2941	Growth Hormone
Hyqvia	J1575	Blood product derivative/ Immune Globulin
Idelvion	J7202	Antihemophilic Agent
Immune Globulin (miscellaneous agents)	J1599, J1566	Blood product derivative/ Immune Globulin
Inflectra	Q5103	Immunosuppressive Agent
Ixinity	J7195	Antihemophilic Agent
Kalbitor	J1290	Hereditary Angioedema Agent (HAE)
Kanuma	J2840	Lysosomal Storage Disorders

Site of Care Medications

Site of Care ensures that members are provided the opportunity to receive the highest quality, lowest cost access to care when receiving these medically appropriate medications. Requests for a site of care other than a non-hospital based facility are reviewed for medical necessity. Non-hospital based facilities may include a physician's office or ambulatory infusion center. This list requiring Site of Care review includes infused or injected medications that are administered by a healthcare provider. A review for prior authorization may also apply to certain medications listed. The policy does not apply to members under the age of 18.

Krystexxa	J2507	Enzyme; anti-Gout agent
Leukine	J2820	Hematopoietic Growth Factor Agents
Lumizyme	J0221	Lysosomal Storage Disorders
Mononine	J7193	Antihemophilic Agent
Naglazyme	J1458	Lysosomal Storage Disorders
Neulasta	J2505	Hematopoietic Growth Factor Agents
Neupogen	J1442	Hematopoietic Growth Factor Agents
Nivestym	Q5110	Hematopoietic Growth Factor Agents
Norditropin	J2941	Growth Hormone
Novoeight	J7182	Antihemophilic Agent
NovoSeven RT	J7189	Antihemophilic Agent
Nplate	J2796	Hematopoietic Growth Factor Agent
Nucala	J2182	Anti-Asthmatic Monoclonal Antibody
Nutropin	J2941	Growth Hormone
Obizur	J7188	Antihemophilic Agent
Ocrevus	J2350	Multiple Sclerosis Agent
Octagam	J1568	Blood product derivative/ Immune Globulin
Omnitrope	J2941	Growth Hormone
Orencia	J0129	Anti-inflammatory Monoclonal Antibody
Privigen	J1459	Blood product derivative/ Immune Globulin
Profilnine	J7194	Antihemophilic Agent
Prolastin-C	J0256	Alpha-1 Proteinase Inhibitors
Prolia	J0897	Monoclonal Antibody Bone-Modifying Agent
Radicava	J1301	Amyotrophic lateral sclerosis (ALS) Agent
Recombinate	J7192	Antihemophilic Agent
Remicade	J1745	Immunosuppressive Agent
Remodulin	J3285	Prostacyclin Agent
Renflexis	Q5104	Immunosuppressive Agent

Site of Care Medications

Site of Care ensures that members are provided the opportunity to receive the highest quality, lowest cost access to care when receiving these medically appropriate medications. Requests for a site of care other than a non-hospital based facility are reviewed for medical necessity. Non-hospital based facilities may include a physician's office or ambulatory infusion center. This list requiring Site of Care review includes infused or injected medications that are administered by a healthcare provider. A review for prior authorization may also apply to certain medications listed. The policy does not apply to members under the age of 18.

Riabni	Q5115	Immunosuppressive Agent; Anti-CD20, *For non-oncology use only
Rituxan	J9312	Immunosuppressive Agent; Anti-CD20, *For non-oncology use only
Rixubis	J7200	Antihemophilic Agent
Ruconest	J0596	Hereditary Angioedema Agent (HAE)
Ruxience	Q5119	Immunosuppressive Agent; Anti-CD20, *For non-oncology use only
Saizen	J2941	Growth Hormone
Serostim	J2941	Growth Hormone
Simponi (SubQ)	J3590 (unclassified biologics Jcode)	Anti-inflammatory Monoclonal Antibody
Simponi Aria	J1602	Anti-inflammatory Monoclonal Antibody
Soliris	J1300	Monoclonal Antibody Agent
Stelara (IV)	J3358	Anti-inflammatory Monoclonal Antibody
Tretten	J7181	Antihemophilic Agent
Truxima	Q5123	Immunosuppressive Agent; Anti-CD20, *For non-oncology use only
Tysabri	J2323	Monoclonal Antibody Agent; Multiple Sclerosis, Crohn's Disease
Tyvaso	J7686	Prostacyclin Agent
Udenyca	Q5111	Hematopoietic Growth Factor Agents
Veletri	J1325	Prostacyclin Agent
Ventavis	Q4074	Prostacyclin Agent
Vimizim	J1322	Lysosomal Storage Disorders
Vpriv	J3385	Lysosomal Storage Disorders
Wilate	J7183	Antihemophilic Agent
Xgeva	J0897	Monoclonal Antibody Bone-Modifying Agent
Xolair	J2357	Anti-Asthmatic Monoclonal Antibody

Site of Care Medications

Site of Care ensures that members are provided the opportunity to receive the highest quality, lowest cost access to care when receiving these medically appropriate medications. Requests for a site of care other than a non-hospital based facility are reviewed for medical necessity. Non-hospital based facilities may include a physician's office or ambulatory infusion center. This list requiring Site of Care review includes infused or injected medications that are administered by a healthcare provider. A review for prior authorization may also apply to certain medications listed. The policy does not apply to members under the age of 18.

Zarxio	Q5101	Hematopoietic Growth Factor Agent
Zemaira	J0256	Alpha-1 Proteinase Inhibitors